TriangleDexamethasone (NCT06390319)
Dexamethasone trial for T-cell Acute Lymphoblastic Leukemia (NCT06390319). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for children aged one to under nineteen with newly diagnosed T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma, or mixed-phenotype acute leukemia, enrolled through INITIALL within three treatment days.
The idea: cell type guides an added drug targeting growth or survival: venetoclax for early-T-precursor, near-ETP, or mixed-phenotype leukemia; dasatinib for other T-cell leukemia; and bortezomib for T-cell lymphoma. Chemotherapy includes spinal-fluid treatment and lasts about two-and-a-quarter years. Researchers compare residual-disease clearance with historical controls.
This phase 2 study plans 100 patients. Seth Karol leads at St. Jude; four US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.